Helen Blair Simpson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11893456/publications.pdf

Version: 2024-02-01

172386 161767 3,174 65 29 54 citations h-index g-index papers 67 67 67 3435 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Randomized, Controlled Trial of Cognitive-Behavioral Therapy for Augmenting Pharmacotherapy in Obsessive-Compulsive Disorder. American Journal of Psychiatry, 2008, 165, 621-630.	4.0	239
2	Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessiveâ€compulsive disorder. World Psychiatry, 2016, 15, 80-81.	4.8	228
3	Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. JAMA Psychiatry, 2013, 70, 1190.	6.0	205
4	Response Versus Remission in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2006, 67, 269-276.	1.1	196
5	Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 2007, 164, 5-53.	4.0	181
6	Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder Journal of Consulting and Clinical Psychology, 2011, 79, 247-252.	1.6	176
7	Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2013, 74, 685-690.	1.1	166
8	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
9	Can delay discounting deliver on the promise of RDoC?. Psychological Medicine, 2019, 49, 190-199.	2.7	117
10	Treatment of Obsessive-Compulsive Disorder by U.S. Psychiatrists. Journal of Clinical Psychiatry, 2006, 67, 946-951.	1.1	87
11	Are there reliable neuropsychological deficits in obsessive–compulsive disorder?. Journal of Psychiatric Research, 2006, 40, 247-257.	1.5	84
12	Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behaviour Research and Therapy, 2010, 48, 941-948.	1.6	70
13	Abnormal hippocampal structure and function in clinical anxiety and comorbid depression. Hippocampus, 2016, 26, 545-553.	0.9	69
14	Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York. Behavior Therapy, 2018, 49, 631-641.	1.3	55
15	Development of a Patient Adherence Scale for Exposure and Response Prevention Therapy. Behavior Therapy, 2010, 41, 30-37.	1.3	54
16	Adding Motivational Interviewing to Exposure and Ritual Prevention for Obsessive–Compulsive Disorder: An Open Pilot Trial. Cognitive Behaviour Therapy, 2008, 37, 38-49.	1.9	48
17	Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder?. Journal of Clinical Psychiatry, 2016, 77, 408-409.	1.1	48
18	Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2011, 72, 567-569.	1.1	46

#	Article	IF	CITATIONS
19	Predictors of Patient Adherence to Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder. Psychotherapy and Psychosomatics, 2012, 81, 124-126.	4.0	46
20	Prevalence of Hoarding Disorder in Individuals at Potential Risk of Eviction in New York City. Journal of Nervous and Mental Disease, 2012, 200, 91-94.	0.5	42
21	Does Extended Release Methylphenidate Help Adults With Hoarding Disorder?. Journal of Clinical Psychopharmacology, 2013, 33, 444-447.	0.7	41
22	Standard criteria for relapse are needed in obsessive-compulsive disorder. Depression and Anxiety, 2005, 21, 1-8.	2.0	40
23	Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention. Behaviour Research and Therapy, 2015, 68, 76-81.	1.6	39
24	Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2012, 73, 1265-1266.	1.1	39
25	Patient Preferences for Obsessive-Compulsive Disorder Treatment. Journal of Clinical Psychiatry, 2010, 71, 1434-1439.	1.1	38
26	Serotonin 2A Receptors in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study with [11C]MDL 100907. Biological Psychiatry, 2011, 70, 897-904.	0.7	37
27	Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5. CNS Spectrums, 2014, 19, 10-20.	0.7	37
28	Using Motivational Interviewing to Enhance Treatment Outcome in People With Obsessive-Compulsive Disorder. Cognitive and Behavioral Practice, 2011, 18, 28-37.	0.9	35
29	Acute effects of cannabinoids on symptoms of obsessiveâ€compulsive disorder: A human laboratory study. Depression and Anxiety, 2020, 37, 801-811.	2.0	34
30	White matter microstructure and its relation to clinical features of obsessive–compulsive disorder: findings from the ENIGMA OCD Working Group. Translational Psychiatry, 2021, 11, 173.	2.4	33
31	To Do or Not to Do? Task Control Deficit in Obsessive-Compulsive Disorder. Behavior Therapy, 2017, 48, 603-613.	1.3	27
32	Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 207-210.	0.7	26
33	Diagnosis and Treatment of a Patient With Both Psychotic and Obsessive-Compulsive Symptoms. American Journal of Psychiatry, 2010, 167, 754-761.	4.0	24
34	Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2015, 76, 440-446.	1.1	24
35	Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2013, 74, 464-469.	1.1	24
36	Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder. Behavior Therapy, 2016, 47, 474-486.	1.3	23

#	Article	IF	Citations
37	Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept. American Journal of Psychiatry, 2016, 173, 1239-1241.	4.0	20
38	Statistical choices can affect inferences about treatment efficacy: A case study from obsessiveâ€"compulsive disorder research. Journal of Psychiatric Research, 2008, 42, 631-638.	1.5	19
39	The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder. Translational Psychiatry, 2022, 12, 70.	2.4	19
40	Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. Revista Brasileira De Psiquiatria, 2014, 36, 3-13.	0.9	18
41	THE RDOC PROJECT: A NEW PARADIGM FOR INVESTIGATING THE PATHOPHYSIOLOGY OF ANXIETY. Depression and Anxiety, 2012, 29, 251-252.	2.0	17
42	Impaired generalization of reward but not loss in obsessive-compulsive disorder. Depression and Anxiety, 2019, 36, 121-129.	2.0	17
43	Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies. Journal of Clinical Psychiatry, 2015, 76, 1653-1657.	1.1	16
44	Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Research - Neuroimaging, 2015, 232, 65-70.	0.9	16
45	Prevalence and Correlates of Difficulty Discarding. Journal of Nervous and Mental Disease, 2013, 201, 795-801.	0.5	14
46	Acceptability of treatments and services for individuals with hoarding behaviors. Journal of Obsessive-Compulsive and Related Disorders, 2016, 11, 1-8.	0.7	14
47	Pharmacological Treatment of Obsessive-Compulsive Disorder. Current Topics in Behavioral Neurosciences, 2009, 2, 527-543.	0.8	13
48	Heterogeneity in Fear Processing across and within Anxiety, Eating, and Compulsive Disorders. Journal of Affective Disorders, 2020, 275, 329-338.	2.0	13
49	Toward identifying reproducible brain signatures of obsessive-compulsive profiles: rationale and methods for a new global initiative. BMC Psychiatry, 2020, 20, 68.	1.1	13
50	Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2017, 78, 466-467.	1.1	13
51	Treatment of Obsessive-Compulsive Disorder in a Nationwide Survey of Office-Based Physician Practice. Psychiatric Services, 2014, 65, 681-684.	1.1	12
52	Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation. JAMA Psychiatry, 2022, 79, 193.	6.0	12
53	What underlies the effect of sleep disruption? The role of alertness in obsessive-compulsive disorder (OCD). Journal of Behavior Therapy and Experimental Psychiatry, 2017, 57, 212-213.	0.6	8
54	Patient Preferences and Acceptability of Evidence-Based and Novel Treatments for Obsessive-Compulsive Disorder. Psychiatric Services, 2017, 68, 250-257.	1.1	8

#	Article	IF	Citations
55	Cutting-edge genetics in obsessive-compulsive disorder. Faculty Reviews, 2020, 9, 30.	1.7	8
56	Latency to treatment seeking in patients with obsessive-compulsive disorder: Results from a large multicenter clinical sample. Psychiatry Research, 2022, 312, 114567.	1.7	8
57	Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention. Psychotherapy and Psychosomatics, 2016, 85, 314-316.	4.0	4
58	Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2018, 79, 17111824.	1.1	4
59	Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning–Based Treatment Outcome in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2019, 39, 91-93.	0.7	3
60	Pilot Study Evaluating Critical Time Intervention for Individuals With Hoarding Disorder at Risk for Eviction. Psychiatric Services, 2020, 71, 405-408.	1.1	3
61	Evidence for trial-by-trial dynamic adjustment of task control in unmedicated adults with OCD. Behaviour Research and Therapy, 2020, 126, 103572.	1.6	2
62	Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder. Current Topics in Behavioral Neurosciences, 2021, 49, 301-329.	0.8	2
63	Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research. Frontiers in Psychiatry, 2021, 12, 626150.	1.3	1
64	Subcortical shape in pediatric and adult obsessiveâ€compulsive disorder. Depression and Anxiety, 2022, 39, 504-514.	2.0	1
65	Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in Psychiatry, 2022, 13, .	1.3	0